<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ziegler A</submitter><funding>Swiss National Science Foundation</funding><pagination>1549-1558</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9388783</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>109(8)</volume><pubmed_abstract>Deoxyhypusine hydroxylase (DOHH) is the enzyme catalyzing the second step in the post-translational synthesis of hypusine [N&lt;sup>ε&lt;/sup>-(4-amino-2-hydroxybutyl)lysine] in the eukaryotic initiation factor 5A (eIF5A). Hypusine is formed exclusively in eIF5A by two sequential enzymatic steps catalyzed by deoxyhypusine synthase (DHPS) and deoxyhypusine hydroxylase (DOHH). Hypusinated eIF5A is essential for translation and cell proliferation in eukaryotes, and all three genes encoding eIF5A, DHPS, and DOHH are highly conserved throughout eukaryotes. Pathogenic variants affecting either DHPS or EIF5A have been previously associated with neurodevelopmental disorders. Using trio exome sequencing, we identified rare bi-allelic pathogenic missense and truncating DOHH variants segregating with disea</pubmed_abstract><journal>American journal of human genetics</journal><pubmed_title>Bi-allelic variants in DOHH, catalyzing the last step of hypusine biosynthesis, are associated with a neurodevelopmental disorder.</pubmed_title><pmcid>PMC9388783</pmcid><funding_grant_id>320020</funding_grant_id><funding_grant_id>179547</funding_grant_id><pubmed_authors>Park MH</pubmed_authors><pubmed_authors>Kury S</pubmed_authors><pubmed_authors>Prouteau C</pubmed_authors><pubmed_authors>Bezieau S</pubmed_authors><pubmed_authors>Faivre L</pubmed_authors><pubmed_authors>Rauch A</pubmed_authors><pubmed_authors>Steindl K</pubmed_authors><pubmed_authors>Maystadt I</pubmed_authors><pubmed_authors>Ziegler A</pubmed_authors><pubmed_authors>Boland A</pubmed_authors><pubmed_authors>Navet B</pubmed_authors><pubmed_authors>Chung WK</pubmed_authors><pubmed_authors>Deleuze JF</pubmed_authors><pubmed_authors>Coubes C</pubmed_authors><pubmed_authors>Le Mao M</pubmed_authors><pubmed_authors>Bonneau D</pubmed_authors><pubmed_authors>Zanoni P</pubmed_authors><pubmed_authors>Tran Mau-Them F</pubmed_authors><pubmed_authors>Hanner AS</pubmed_authors><pubmed_authors>Kar RK</pubmed_authors><pubmed_authors>Lenaers G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Bi-allelic variants in DOHH, catalyzing the last step of hypusine biosynthesis, are associated with a neurodevelopmental disorder.</name><description>Deoxyhypusine hydroxylase (DOHH) is the enzyme catalyzing the second step in the post-translational synthesis of hypusine [N&lt;sup>ε&lt;/sup>-(4-amino-2-hydroxybutyl)lysine] in the eukaryotic initiation factor 5A (eIF5A). Hypusine is formed exclusively in eIF5A by two sequential enzymatic steps catalyzed by deoxyhypusine synthase (DHPS) and deoxyhypusine hydroxylase (DOHH). Hypusinated eIF5A is essential for translation and cell proliferation in eukaryotes, and all three genes encoding eIF5A, DHPS, and DOHH are highly conserved throughout eukaryotes. Pathogenic variants affecting either DHPS or EIF5A have been previously associated with neurodevelopmental disorders. Using trio exome sequencing, we identified rare bi-allelic pathogenic missense and truncating DOHH variants segregating with disea</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Aug</publication><modification>2026-05-27T21:04:17.369Z</modification><creation>2025-02-18T22:34:42.541Z</creation></dates><accession>S-EPMC9388783</accession><cross_references><pubmed>35858628</pubmed><doi>10.1016/j.ajhg.2022.06.010</doi></cross_references></HashMap>